The Center for Infectious Disease Research and Vaccinology, South Dakota State University, Brookings, South Dakota, USA.
Infect Immun. 2014 May;82(5):1823-32. doi: 10.1128/IAI.01394-13. Epub 2014 Feb 18.
A long-standing challenge in developing vaccines against enterotoxigenic Escherichia coli (ETEC), the most common bacteria causing diarrhea in children of developing countries and travelers to these countries, is to protect against heat-stable toxin type Ib (STa or hSTa). STa and heat-labile toxin (LT) are virulence determinants in ETEC diarrhea. LT antigens are often used in vaccine development, but STa has not been included because of its poor immunogenicity and potent toxicity. Toxic STa is not safe for vaccines, but only STa possessing toxicity is believed to be able to induce neutralizing antibodies. However, recent studies demonstrated that nontoxic STa derivatives (toxoids), after being fused to an LT protein, induced neutralizing antibodies and suggested that different STa toxoids fused to an LT protein might exhibit different STa antigenic propensity. In this study, we selected 14 STa toxoids from a mini-STa toxoid library based on toxicity reduction and reactivity to anti-native STa antibodies, and genetically fused each toxoid to a monomeric double mutant LT (dmLT) peptide for 14 STa-toxoid-dmLT toxoid fusions. These toxoid fusions were used to immunize mice and were characterized for induction of anti-STa antibody response. The results showed that different STa toxoids (in fusions) varied greatly in anti-STa antigenicity. Among them, STaN12S, STaN12T, and STaA14H were the top toxoids in inducing anti-STa antibodies. In vitro neutralization assays indicated that antibodies induced by the 3×STaN12S-dmLT fusion antigen exhibited the greatest neutralizing activity against STa toxin. These results suggested 3×STaN12S-dmLT is a preferred fusion antigen to induce an anti-STa antibody response and provided long-awaited information for effective ETEC vaccine development.
肠产毒性大肠杆菌(ETEC)是发展中国家儿童和前往这些国家旅行者腹泻最常见的细菌,长期以来一直面临着开发疫苗的挑战,因为它能够产生耐热毒素 Ib 型(STa 或 hSTa)。STa 和不耐热毒素(LT)是 ETEC 腹泻的毒力决定因素。LT 抗原常用于疫苗开发,但由于 STa 免疫原性差且毒性强,因此并未包含在内。毒性 STa 对疫苗不安全,但只有具有毒性的 STa 才被认为能够诱导中和抗体。然而,最近的研究表明,非毒性 STa 衍生物(类毒素)与 LT 蛋白融合后能够诱导中和抗体,并表明不同的 STa 类毒素与 LT 蛋白融合可能具有不同的 STa 抗原倾向。在这项研究中,我们根据毒性降低和对天然 STa 抗体的反应性,从迷你 STa 类毒素文库中选择了 14 种 STa 类毒素,并将每种类毒素基因融合到单体双突变 LT(dmLT)肽上,构建了 14 种 STa 类毒素-dmLT 类毒素融合物。这些类毒素融合物被用于免疫小鼠,并对其诱导抗 STa 抗体反应的特性进行了表征。结果表明,不同的 STa 类毒素(在融合物中)在抗 STa 抗原性方面存在很大差异。其中,STaN12S、STaN12T 和 STaA14H 是诱导抗 STa 抗体的最佳类毒素。体外中和测定表明,由 3×STaN12S-dmLT 融合抗原诱导的抗体对 STa 毒素表现出最大的中和活性。这些结果表明 3×STaN12S-dmLT 是诱导抗 STa 抗体反应的首选融合抗原,为有效 ETEC 疫苗的开发提供了期待已久的信息。